Fondazione Istituto Italiano Di Tecnologia

University of California

Alma Mater Studiorum-Universitá Di Bologna

Universitá Degli Studi Di Padova

Fondazione Istituto Italiano Di Technologia

Istituto Europeo Di Oncologia S.r.l.

Tes Pharma S.r.l.

Jose Antonio Ortega Martinez

Marco De Vivo

Sohail Jahid

Anand Ganesan

Roberto Pellicciari

Francesca De Franco

Pier Giuseppe Pelicci

Marinella Roberti

Jose Manuel Arencibia Jimenez

Claudia Sissi

Anna Minarini

Giuseppina Di Stefano

Andrea Cavalli

Domenico Milano

Marcella Manerba

Greta Bagnolini

Saverio Minucci

Viola Previtali

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of formula (I) and their uses, in particular in the treatment of diseases or disorders associated to increased relative to physiological or desired RhoJ/Cdc42 levels of expression or function.

Substituted pyrimidines and 1,3,5-triazines as RHOJ inhibitors

The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular for the use in the treatment of diseases or disorders wherein disrupting Rad51-BRCA2 interaction is beneficial.

Compounds and compositions for the treatment of tumors

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular in the treatment of diseases or disorders associated to increased relative to physiological or desired RhoJ/Cdc42 levels of expression or function.

Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof:  It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular in the treatment of diseases or disorders associated to increased relative to physiological or desired RhoJ/Cdc42 levels of expression or function.

Substituted pyrimidines as inhibitors for a Rho family of GTP-ases

The present invention concerns 4-amino-2-pyrido-bicyclic pyrimidines of Formula (I) that function as type II topoisomerase inhibitors and their use thereof as medicaments especially in the treatment of cancer. The invention also provides a method for the manufacture of 4-amino-2-pyrido bicyclic pyrimidines of Formula (I).

4-amino-2-pyrido-bicyclic pyrimidines and use thereof as topoisomerase II inhibitors

Growing community of inventors

Genoa, Italy

Jose Antonio Ortega Martinez